Cartesian Therapeutics Files 8-K for Corporate Communications

Ticker: RNAC · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1453687

Cartesian Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCartesian Therapeutics, Inc. (RNAC)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, regulatory-filing, communications

TL;DR

**RNAC filed an 8-K for corporate communications, signaling potential big news ahead.**

AI Summary

Cartesian Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to satisfy filing obligations related to written communications and soliciting materials under various SEC rules, including Rule 425 and Rule 14a-12. This filing indicates that the company, whose common stock trades under the symbol RNAC on The Nasdaq Stock Market LLC, is actively engaged in corporate communications, likely in connection with a significant event such as a merger, acquisition, or other material transaction. For investors, this matters because it signals ongoing corporate activity that could impact the company's valuation, strategic direction, or future prospects, potentially leading to increased volatility or a re-evaluation of the stock.

Why It Matters

This filing signals active corporate communications, which often precede or accompany significant business events like mergers or new offerings, potentially impacting stock value.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying corporate communications it references could involve significant risks or opportunities for investors.

Analyst Insight

Investors should monitor Cartesian Therapeutics, Inc. (RNAC) for subsequent filings or announcements, as the referenced corporate communications could reveal significant strategic developments. Reviewing the content of the communications under Rule 425 and Rule 14a-12 would be crucial.

Key Numbers

  • 001-37798 — Commission File Number (identifies the company's registration with the SEC)
  • $0.0001 — Par Value (par value of the Common Stock)

Key Players & Entities

  • Cartesian Therapeutics, Inc. (company) — the registrant filing the 8-K
  • RNAC (company) — trading symbol for Cartesian Therapeutics, Inc. Common Stock
  • The Nasdaq Stock Market LLC (company) — exchange where Cartesian Therapeutics, Inc. Common Stock is registered
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • Delaware (company) — state of incorporation for Cartesian Therapeutics, Inc.
  • 001-37798 (dollar_amount) — Commission File Number

FAQ

What is the primary purpose of Cartesian Therapeutics, Inc.'s 8-K filing on January 8, 2024?

The primary purpose of the 8-K filing on January 8, 2024, is to satisfy the registrant's filing obligations under various provisions, specifically checking boxes for written communications pursuant to Rule 425 and soliciting material pursuant to Rule 14a-12 under the Exchange Act.

What is the trading symbol and exchange for Cartesian Therapeutics, Inc.'s common stock?

The common stock of Cartesian Therapeutics, Inc. trades under the symbol RNAC on The Nasdaq Stock Market LLC.

What is the state of incorporation for Cartesian Therapeutics, Inc.?

Cartesian Therapeutics, Inc. is incorporated in Delaware.

What is the business address and phone number listed for Cartesian Therapeutics, Inc. in the filing?

The business address is 704 Quince Orchard Road, Gaithersburg, MD 20878, and the phone number is (617) 923-1400.

Does this 8-K filing indicate that Cartesian Therapeutics, Inc. is an emerging growth company?

The filing includes a checkbox to 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act,' but the box is not checked, so the filing does not explicitly state whether they are an emerging growth company.

Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-08 08:45:40

Key Financial Figures

  • $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Cartesian Therapeutics, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. Additionally, on January 8, 2024, the Company issued press releases announcing long-term follow-up data from its Phase 2a study of Descartes-08 in patients with myasthenia gravis and announcing its 2024 strategic priorities, respectively. These press releases are attached to this Current Report on Form 8-K as Exhibits 99.2 and 99.3, respectively. The information in Item 7.01 of this Form 8-K, including Exhibits 99.1, 99.2, and 99.3 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1, 99.2, or 99.3, except as required by law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Corporate slide presentation of Cartesian Therapeutics, Inc. dated January 2024 99.2 Press release announcing long-term follow-up data from Phase 2a study of Descartes-08 in myasthenia gravis issued on January 8, 2024 99.3 Press release announcing the Company's 2024 strategic priorities issued on January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.